Abstract
Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), is the new first line standard of care in metastatic non‐small cell lung cancer (NSCLC) based on improvements in overall survival (OS), control of central nervous system (CNS) disease, and a superior toxicity profile. This commentary highlights interim results from the ADAURA trial, continuing the effort to establish a role for EGFR TKIs in the adjuvant setting.